Anti-VGFR3/ FLT-4/ FLT4 monoclonal antibody

Anti-VGFR3/ FLT-4/ FLT4 antibody for FACS & in-vivo assay

Target products collectionGo to FLT-4/FLT4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T07303-Ab-1/ GM-Tg-hg-T07303-Ab-2Anti-Human FLT-4/FLT4 monoclonal antibodyHuman
GM-Tg-rg-T07303-Ab-1/ GM-Tg-rg-T07303-Ab-2Anti-Rat FLT-4/FLT4 monoclonal antibodyRat
GM-Tg-mg-T07303-Ab-1/ GM-Tg-mg-T07303-Ab-2Anti-Mouse FLT-4/FLT4 monoclonal antibodyMouse
GM-Tg-cynog-T07303-Ab-1/ GM-Tg-cynog-T07303-Ab-2Anti-Cynomolgus/ Rhesus macaque FLT-4/FLT4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T07303-Ab-1/ GM-Tg-felg-T07303-Ab-2Anti-Feline FLT-4/FLT4 monoclonal antibodyFeline
GM-Tg-cang-T07303-Ab-1/ GM-Tg-cang-T07303-Ab-2Anti-Canine FLT-4/FLT4 monoclonal antibodyCanine
GM-Tg-bovg-T07303-Ab-1/ GM-Tg-bovg-T07303-Ab-2Anti-Bovine FLT-4/FLT4 monoclonal antibodyBovine
GM-Tg-equg-T07303-Ab-1/ GM-Tg-equg-T07303-Ab-2Anti-Equine FLT-4/FLT4 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T07303-Ab-1/ GM-Tg-hg-T07303-Ab-2; GM-Tg-rg-T07303-Ab-1/ GM-Tg-rg-T07303-Ab-2;
GM-Tg-mg-T07303-Ab-1/ GM-Tg-mg-T07303-Ab-2; GM-Tg-cynog-T07303-Ab-1/ GM-Tg-cynog-T07303-Ab-2;
GM-Tg-felg-T07303-Ab-1/ GM-Tg-felg-T07303-Ab-2; GM-Tg-cang-T07303-Ab-1/ GM-Tg-cang-T07303-Ab-2;
GM-Tg-bovg-T07303-Ab-1/ GM-Tg-bovg-T07303-Ab-2; GM-Tg-equg-T07303-Ab-1/ GM-Tg-equg-T07303-Ab-2
Products NameAnti-FLT-4/FLT4 monoclonal antibody
Formatmab
Target NameFLT-4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FLT-4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species VGFR3/ FLT-4/ FLT4 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T07303-Ag-1fms-related tyrosine kinase 4 (FLT4) protein


    Target information

    Target IDGM-T07303
    Target NameFLT-4
    Gene ID2324,14257,114110,716412,481464,101094727,338031,100066773
    Gene Symbol and SynonymsCHTD7,Chy,FLT-4,FLT4,FLT41,LMPH1A,LMPHM1,PCL,VEGFR-3,VEGFR3
    Uniprot AccessionP35916,Q91ZT1
    Uniprot Entry NameVGFR3_HUMAN,VGFR3_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000037280
    Target ClassificationKinase, Tumor-associated antigen (TAA)

    The target: FLT-4, gene name: FLT4, also named as FLT-41, LMPH1A, PCL, VEGFR-3, VEGFR3, FLT4. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.